title: Inhibition of adenylyl cyclase by caveolin peptides.
abstract: Caveolae and their principal component caveolin have been implicated in playing a major role in G protein-mediated transmembrane signaling. We examined whether caveolin interacts with adenylyl cyclase, an effector of G protein signaling, using a 20-mer peptide derived from the N-terminus scaffolding domain of caveolin-1. When tissue adenylyl cyclases were examined, cardiac adenylyl cyclase was inhibited more potently than other tissue adenylyl cyclases. The caveolin-1 peptide inhibited type V, as well as type III adenylyl cyclase, overexpressed in insect cells, whereas the same peptide had no effect on type II. The caveolin-3 scaffolding domain peptide similarly inhibited type V adenylyl cyclase. In contrast, peptides derived from the caveolin-2 scaffolding domain and a caveolin-1 nonscaffolding domain had no effect. Kinetic studies showed that the caveolin-1 peptide decreased the maximal rate (Vmax) value of type V without changing the Michaelis constant (Km) value for the substrate ATP. Studies with various truncations and point mutations of this peptide revealed that a minimum of 16 amino acid residues and intact aromatic residues are important for the inhibitory effect. The potency of inhibition was greater when adenylyl cyclase was in stimulated condition vs. basal condition. Thus, caveolin may be another cellular component that regulates adenylyl cyclase catalytic activity. Our results also suggest that the caveolin peptide may be used as an isoform-selective inhibitor of adenylyl cyclase.
authors.affiliation: Cardiovascular and Pulmonary Research Institute, Allegheny University of the Health Sciences, Pittsburgh, Pennsylvania 15212, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Toya
authors.forename: C
authors.initials: C
authors.lastname: Schwencke
authors.forename: J
authors.initials: J
authors.lastname: Couet
authors.forename: M P
authors.initials: MP
authors.lastname: Lisanti
authors.forename: Y
authors.initials: Y
authors.lastname: Ishikawa
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D000595:Amino Acid Sequence; D000818:Animals; D051242:Caveolin 1; D022461:Caveolins; D005576:Colforsin / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D017353:Gene Deletion; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D007700:Kinetics; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D051379:Mice; D016296:Mutagenesis; D010446:Peptide Fragments / Q000494:pharmacology*; D017354:Point Mutation; D013329:Structure-Activity Relationship
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; C495541:Cav1 protein, mouse; D051242:Caveolin 1; D022461:Caveolins; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D010446:Peptide Fragments; D005576:Colforsin; D016244:Guanosine 5'-O-(3-Thiotriphosphate)